# Tuberculosis Research and Epidemiology

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/tuberculosis-research-and-epidemiology/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers encompasses a wide range of topics related to tuberculosis, including research on Mycobacterium tuberculosis, drug resistance, immune response, diagnosis methods, vaccine development, host-pathogen interaction, treatment regimens, epidemiology, and genetic diversity. The papers cover various aspects of tuberculosis from molecular mechanisms to global epidemiological trends. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10038 |
| Works | 254 |

## Topic papers all

Showing 15 of 254.

- [Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis](https://scholariq.org/papers/discovery-research-and-development-of-new-antibiotics-the-who-priority-list-of/)
- [American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis](https://scholariq.org/papers/american-thoracic-society-centers-for-disease-control-and-prevention-infectious/)
- [Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis](https://scholariq.org/papers/official-american-thoracic-society-centers-for-disease-control-and-prevention/)
- [Genomewide Association Study of Leprosy](https://scholariq.org/papers/genomewide-association-study-of-leprosy/)
- [Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle](https://scholariq.org/papers/direct-recognition-of-the-mycobacterial-glycolipid-trehalose-dimycolate-by-c/)
- [Towards tuberculosis elimination: an action framework for low-incidence countries](https://scholariq.org/papers/towards-tuberculosis-elimination-an-action-framework-for-low-incidence-countries/)
- [Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis](https://scholariq.org/papers/treatment-correlates-of-successful-outcomes-in-pulmonary-multidrug-resistant/)
- [Management of latent<i>Mycobacterium tuberculosis</i>infection: WHO guidelines for low tuberculosis burden countries](https://scholariq.org/papers/management-of-latent-i-mycobacterium-tuberculosis-i-infection-who-guidelines-for/)
- [Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis](https://scholariq.org/papers/best-drug-treatment-for-multidrug-resistant-and-extensively-drug-resistant/)
- [Risk of Tuberculosis From Exposure to Tobacco Smoke](https://scholariq.org/papers/risk-of-tuberculosis-from-exposure-to-tobacco-smoke/)
- [Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis](https://scholariq.org/papers/interferon-release-assays-for-the-diagnosis-of-active-tuberculosis-a-systematic/)
- [Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients](https://scholariq.org/papers/multidrug-resistant-pulmonary-tuberculosis-treatment-regimens-and-patient/)
- [Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan1](https://scholariq.org/papers/epidemiology-of-pulmonary-nontuberculous-mycobacterial-disease-japan1/)
- [The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement](https://scholariq.org/papers/the-risk-of-tuberculosis-related-to-tumour-necrosis-factor-antagonist-therapies/)
- [Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline](https://scholariq.org/papers/treatment-of-drug-resistant-tuberculosis-an-official-ats-cdc-ers-idsa-clinical/)

## Topic primary papers

Showing 15 of 149.

- [Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis](https://scholariq.org/papers/official-american-thoracic-society-centers-for-disease-control-and-prevention/)
- [Towards tuberculosis elimination: an action framework for low-incidence countries](https://scholariq.org/papers/towards-tuberculosis-elimination-an-action-framework-for-low-incidence-countries/)
- [Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis](https://scholariq.org/papers/treatment-correlates-of-successful-outcomes-in-pulmonary-multidrug-resistant/)
- [Management of latent<i>Mycobacterium tuberculosis</i>infection: WHO guidelines for low tuberculosis burden countries](https://scholariq.org/papers/management-of-latent-i-mycobacterium-tuberculosis-i-infection-who-guidelines-for/)
- [Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis](https://scholariq.org/papers/best-drug-treatment-for-multidrug-resistant-and-extensively-drug-resistant/)
- [Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis](https://scholariq.org/papers/interferon-release-assays-for-the-diagnosis-of-active-tuberculosis-a-systematic/)
- [Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients](https://scholariq.org/papers/multidrug-resistant-pulmonary-tuberculosis-treatment-regimens-and-patient/)
- [The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement](https://scholariq.org/papers/the-risk-of-tuberculosis-related-to-tumour-necrosis-factor-antagonist-therapies/)
- [Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline](https://scholariq.org/papers/treatment-of-drug-resistant-tuberculosis-an-official-ats-cdc-ers-idsa-clinical/)
- [The global burden of tuberculosis: results from the Global Burden of Disease Study 2015](https://scholariq.org/papers/the-global-burden-of-tuberculosis-results-from-the-global-burden-of-disease/)
- [Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics](https://scholariq.org/papers/epidemiological-benefits-of-more-effective-tuberculosis-vaccines-drugs-and/)
- [The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis](https://scholariq.org/papers/the-risk-of-tuberculosis-in-children-after-close-exposure-a-systematic-review/)
- [Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in <i>Mycobacterium tuberculosis</i>](https://scholariq.org/papers/identification-of-a-nitroimidazo-oxazine-specific-protein-involved-in-pa-824/)
- [Tuberculosis after Solid‐Organ Transplant: Incidence, Risk Factors, and Clinical Characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort](https://scholariq.org/papers/tuberculosis-after-solid-organ-transplant-incidence-risk-factors-and-clinical/)
- [Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study](https://scholariq.org/papers/effectiveness-and-safety-of-bedaquiline-containing-regimens-in-the-treatment-of/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.